FIL Ltd cut its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 4.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,528,117 shares of the company's stock after selling 79,243 shares during the quarter. FIL Ltd owned approximately 0.13% of Teva Pharmaceutical Industries worth $33,680,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Oarsman Capital Inc. purchased a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter valued at approximately $29,000. Wilmington Savings Fund Society FSB acquired a new position in shares of Teva Pharmaceutical Industries during the third quarter valued at $50,000. Ameliora Wealth Management Ltd. bought a new position in Teva Pharmaceutical Industries during the 4th quarter valued at $66,000. IFP Advisors Inc raised its holdings in shares of Teva Pharmaceutical Industries by 96.1% in the 4th quarter. IFP Advisors Inc now owns 3,999 shares of the company's stock worth $88,000 after purchasing an additional 1,960 shares in the last quarter. Finally, Quadrant Capital Group LLC raised its holdings in Teva Pharmaceutical Industries by 27.7% during the 4th quarter. Quadrant Capital Group LLC now owns 4,377 shares of the company's stock worth $96,000 after buying an additional 949 shares during the period. 54.05% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Several research firms recently issued reports on TEVA. Bank of America decreased their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a report on Thursday, March 6th. StockNews.com upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Friday, April 4th. UBS Group dropped their price target on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a research note on Thursday, January 30th. Piper Sandler upped their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a report on Friday, January 17th. Finally, Barclays dropped their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a research note on Thursday, January 30th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $23.43.
Check Out Our Latest Stock Report on TEVA
Teva Pharmaceutical Industries Stock Performance
Shares of NYSE:TEVA traded up $0.12 during trading on Monday, hitting $13.58. The company's stock had a trading volume of 10,291,808 shares, compared to its average volume of 9,919,301. The company has a 50-day moving average of $15.79 and a 200-day moving average of $17.82. The firm has a market cap of $15.40 billion, a price-to-earnings ratio of -9.37, a P/E/G ratio of 1.44 and a beta of 0.72. Teva Pharmaceutical Industries Limited has a 12 month low of $12.47 and a 12 month high of $22.80. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75.
Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, topping analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. On average, sell-side analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current year.
Teva Pharmaceutical Industries Company Profile
(
Free Report)
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
Featured Articles
Before you consider Teva Pharmaceutical Industries, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.
While Teva Pharmaceutical Industries currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
